Retroviral vectors derived from murine leukemia virus (MLV) are amongst the most
frequently utilized vectors in gene therapy approaches such as the genetic modification of …

Retroviral vectors derived from murine leukemia virus (MLV) are used in somatic gene
therapy applications eg for genetic modification of hematopoietic stem cells. Recently, we …

Viral vector particles derived from murine leukemia virus (MLV) mediate highly efficient
stable gene transfer used in gene therapeutic approaches and in the generation of …

Retroviral vectors based on Moloney Murine Leukemia Virus (MLV), described more than 15
years ago (1), first entered clinical trials in 1990 (2). Since then, a greater understanding of …

To date, only adherent cell lines have been used for the generation of packaging cells for
the production of type C retrovirus vectors. The large-scale production of high titre retrovirus …

Successful retroviral-mediated gene therapy will depend on safe, efficient packaging cell
lines for vector particle production. Existing packaging lines for murine leukemia virus (MLV) …

We report increased transduction of human hematopoietic progenitor cells through a
combination of novel retroviral vector packaging cell lines, and improved vector supernatant …

The broad application of retroviral vectors for gene delivery is still hampered by the difficulty
to reproducibly establish high vector producer cell lines generating sufficient amounts of …

We have previously reported the development of improved MLV-based retroviral vectors
whose prototype is entitled MT (Kim et al, J. Virol. 72: 994–1044; Yu et al, Gene Therapy 7 …

Several barriers exist to high-efficiency transfer of therapeutic genes into human
hematopoietic stem cells (HSCs) using complex oncoretroviral vectors. Human clinical trials …